Myriad Sponsors Clinical Trial

Salt Lake City, Utah-based Myriad Genetics announced this morning that the company is sponsoring a clinical trial of patients with pancreatic cancer. The study, run by researchers at Johns Hopkins University, will enroll patients with untreated, advanced or recurrent pancreatic cancer and a mutation in the BRCA2 gene. Myriad said that the trial will determine whether the sensitivity of the pancreatic cancer to its agent mitomycin-C holds true in humans as it did in earlier studies.